About Curon Medical
Devices for the minimally invasive treatment of gastro-intestinal diseases, focusing initially on Gastro Esophageal Reflux Disease (GERD), and fecal incontinence. IPO 2000. NASDAQ: CURN.
Missing: Curon Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Curon Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Curon Medical Frequently Asked Questions (FAQ)
When was Curon Medical founded?
Curon Medical was founded in 1997.
Where is Curon Medical's headquarters?
Curon Medical's headquarters is located at 46117 Landing Parkway, Fremont.
What is Curon Medical's latest funding round?
Curon Medical's latest funding round is PIPE.
How much did Curon Medical raise?
Curon Medical raised a total of $46.03M.
Who are the investors of Curon Medical?
Investors of Curon Medical include SF Capital Group, Iroquois Capital Group, Meadowbrook Capital Management, Lewis Asset Management, Balyasny Asset Management and 22 more.
Who are Curon Medical's competitors?
Competitors of Curon Medical include Gynesonics, Endologix, Uromedica, Torax Medical, Sequent Medical and 15 more.
Compare Curon Medical to Competitors
Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.
Kyphon develops and markets medical devices designed to restore spinal function using minimally invasive technologies. The company's KyphX(R) line of products is used in balloon kyphoplasty, a minimally invasive procedure to treat spinal fractures caused by osteoporosis or cancer. More information about the company can be found at www.kyphon.com.
Afferent Corporation, based in Providence, Rhode Island, is developing of a new class of medical devices to treat chronic neurologic dysfunction. Its lead technology enhances the function of mechanoreceptor cells involved in sensory perception as a means to restore brain function following a stroke, to address complications resulting from diabetic neuropathy, and to improve elderly balance. Afferent's development efforts are being pursued in collaboration with leading biomedical and clinical researchers throughout the United States. Building on this technology platform, Afferent aims to establish a leadership position in the emerging field of neurotherapeutic devices.
Ecochlor develops ballast water treatment systems that have been designed to safely and economically eliminate the worldwide transfer of aquatic invasive species and human pathogens such as cholera, in ship ballast water.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.